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ABSTRACT 
Background Recent trials on rectal cancer have demonstrated significant improvements in local 
recurrence without improvements in overall survival. The aim of this paper was to define the influence of 
local recurrence on survival in a prospective series of patients who underwent R0 or R1 resections for 
rectal cancer. 
Methods Patients presenting with rectal cancer from 1996 to 2012 were prospectively audited. The study 
included patients who underwent an R0 or R1 resection. Local recurrence was defined as cancer regrowth 
detected in the pelvis regardless of whether or not new metastases were found elsewhere. Kaplan-Meier 
curves, smoothed hazard functions and Cox models using both time since diagnosis and age as the time 
scale were used to define the influence of local recurrence on overall survival.  
Results   The study involved 483 patients, of mean age 66 years (SD=13) and a median follow-up of 5.2 
years. The results at 5 years were: overall survival 71% (95%CI 66-75), local recurrence 7% (95%CI 5-
10), and distant recurrence 18% (95% CI 14-22). Patients diagnosed with local recurrence died faster than 
patients diagnosed with either distant recurrence or no recurrence, and this was particularly obvious for 
younger patients (local HR 54, 95%CI 12-253 and distant HR19, 95%CI 4-80).  Local recurrence that 
developed early following surgery also had worse survival outcomes.  
Conclusions  Within this cohort of rectal cancer patients, the early development of local recurrence was 
the single most important indicator of a reduced survival, and carried a worse prognosis than the 






A major emphasis over the last 20 years in the management of rectal cancer has been to reduce the rates 
of local recurrence. This is because it is considered to be both an important prognostic factor and a 
clinical indicator of the quality of treatment. During this period a number of reports have demonstrated a 
significant reduction in the rates of local recurrence
1-6
. Yet despite this, three recent clinical trials 
reporting mature long-term results, have highlighted significant improvements in local recurrence without 
an improvement in survival
5,6
. A pooled analysis of the EORTC trial 22921 and the FFCD 9203 trial 
(evaluating pre operative chemo-radiotherapy versus radiotherapy regimes) with a median follow-up of 6 
years showed a significant decrease in local recurrence (11% vs 15%) but no difference in the 5 year 
overall survival (66% vs 66%)
6
.  Similarly, the Dutch TME (Total Mesorectal Excision) and radiotherapy 
trial reported 12 year follow-up results that demonstrated a significant decrease in local recurrence (5% vs 
11%) and no difference in overall survival (48% vs 49%)
5
(Table I).  
 
The aim of this study was to determine the rate and pattern of recurrence in patients undergoing R0 or R1 
resections for rectal cancer and to quantify its influence on overall survival using Cox models and to 




This study included all patients with biopsy proven adenocarcinoma of the rectum who were managed 
from 1996 to 2012 by a single colorectal surgeon. Patients were excluded if they did not undergo surgery 
or if the resection was R2 (i.e. leaving obvious macroscopic disease). Patients in this cohort diagnosed 
from 1996-2006 were treated predominantly in the public health care system whereas patients diagnosed 
after 2006 were treated in a private hospital.  This meant that calendar year and hospital type were 
correlated. Surgical procedures included high anterior resections, low anterior resections (anastomosis 
within 10 cm of the anal verge), ultralow anterior resections (i.e. total mesorectal excision with an 
anastomosis within 6cm of the anal verge), and local excisions. The height of the cancer was measured 
from the inferior aspect of the internal anal sphincter to the lower tumour border. Tumour stage was 




All patients were prospectively entered into a database 
(Filemaker Pro) that was maintained by a research nurse. Patients were followed up as per a defined plan 
that included six monthly visits for five years, a thoraco-abdominal CT scan every 12 months, a 
colonoscopy at 12 months, three years and five years.  
 
Neoadjuvant therapy in the form of long course radiotherapy and chemotherapy (CMT) was offered to all 
patients presenting electively with distal rectal cancers (within 12 cm of the anal verge) and imaging 
evidence of either a T3/4 rectal tumour and/or involved mesorectal lymph nodes. The preoperative 
clinical and imaging stage was used for the purposes of the analysis if there was no residual tumour in the 
specimen after preoperative CMT. For patients in whom the tumour was down staged, the preoperative T 
staging was used. N staging relied upon the histological evaluation. Patients with residual mucin pools 
and no tumour within the nodes were classified as positive. Patients receiving CMT were offered 
postoperative chemotherapy to complete their treatment.  
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Recurrence was defined as the development of either biopsy proven or radiological evidence (including a 
positive PET scan) of tumour regrowth following the initial surgery. Local recurrence was defined as 
cancer regrowth detected in the pelvis regardless of whether or not new metastases were found elsewhere. 
All patients who developed recurrent disease were assessed for possible curative resection. 
 
Age and year at diagnosis were collapsed into grouped variables. A time-to-event analysis was performed 
on the rectal cancer patient cohort using non-parametric Kaplan-Meier, log-rank tests and smoothed 
hazard functions and semi-parametric Cox models. The hazard function or force of mortality can be 
interpreted as a measure of the tendency to die at a given point in time provided the patient has survived 
up to that time point.  The main outcome measure was all-cause mortality with local and distant disease 
recurrence treated as time dependent covariates. A separate investigation of factors present at time of 
surgery that were associated with the rate of recurrence was also performed but using time since diagnosis 
as the time scale. It is traditional to use time since diagnosis as the origin for cancer survival studies.  An 
alternative is to use age as the time scale. When age is used as the time scale, the age effect on survival is 
removed as it is absorbed into the unspecified baseline hazard. Using age as the time scale is useful when 
investigating all-cause mortality outcomes (i.e. overall survival) as these are strongly associated with age 




Patients were followed up until date of death or study censor date (31st March 2012).  Date of death was 
determined from linkage of patient identifiers to the state based death registry on a regular basis.   Loss to 
follow-up for recurrence was expected to be minimal because few patients left the state (three patients 
identified). Likelihood ratio tests were used to include or exclude covariates from the adjusted (and most 
parsimonious) model and to identify any potential plausible interaction terms at the 5% level.  Chi - 
square, Fisher’s exact, and rank sum tests were also used to test equality in proportions and medians 







There were 483 patients with rectal cancer in the study cohort with more males than females (Table 2).   
Mean age at diagnosis was 66.1 (SD= 13.1) years with ages ranging from 28 to 93 years. Median length 
of follow-up was 5.2 years from time of diagnosis and ranged from 0.2 to 16 years.  There were 179 
deaths during follow-up, six patients died in the 30 day postoperative period (1.2%), and 25 patients 
developed local recurrence. Of the patients who developed local recurrence, 9 (36%) had isolated disease 
within the pelvis, the remainder had systemic disease as well.  The five year outcome proportions were: 
overall survival 70.9% (95%CI 66.4-75), local recurrence 6.8% (95%CI 4.6-10), distant recurrence 17.6% 
(95%CI 14.1-21.9). When patients who had R1 resections or local excisions were excluded, the five year 
local recurrence rate for R0 resections was 3.1% (95%CI 1.7-5.7%).  
   
A univariate analysis of equality of survivorship function by various individual demographic and clinical 
parameters is summarized in Table 2.   Survival outcomes differed by patient age, stage at diagnosis, 
resection status, recurrence, and curative intent.  Survival was also observed to differ by year of 
diagnosis, type of operation, and whether extramural venous invasion was documented.  There was no 
difference in overall survival by sex, height of tumour, lymph node involvement, chemotherapy or 
radiotherapy when each variable was tested individually.  
 
The univariate log rank tests indicated that patients had a different survival experience after a local or 
distant recurrence (Table 2).  A Kaplan -Meir curve of the survivorship function by recurrence state and 
using time since diagnosis as the analysis time shows that after patients were diagnosed with local 
recurrence they appeared to die faster than patients diagnosed with distant recurrence or no recurrence 
(Fig 1A).   A smoothed hazard function of the same data (Fig 1B) shows that the rate of dying following a 
local recurrence was highest when it occurred within a short time of diagnosis (less than two years) then 
falling to a stable but high rate.  The rate of dying following a distant recurrence appeared to increase 
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with time since diagnosis, peaking at around four years post diagnosis and then falling to levels similar to 
patients without a recurrence recorded. 
 
Age was used as the analysis time scale to investigate whether the rates of dying following a recurrence 
varied by age (Fig 2A).  Of patients with a local recurrence, those who were aged 50 - 65 years showed a 
tendency to die faster than older patients.  In contrast, patients with distant recurrence had an increasing 
mortality rate with age, similar to patients who did not have a recurrence recorded; albeit at a higher rate.   
Using attained age as the time scale, factors associated with all-cause mortality of the rectal cancer cohort 
were estimated using a Cox proportional hazards regression model (Table 3).  After experiencing either a 
local or distant recurrence of disease, the relative rate of dying increased significantly although this 
depended on the age at diagnosis.  Patients diagnosed when younger than 60 years of age or older than 70 
years died more quickly after local and distant recurrence compared to similar aged patients who did not 
have a recurrence.  Whereas in patients diagnosed when aged 60-79 years there was no difference in the 
rate of dying after a local recurrence and only a smaller increased risk of dying after distant recurrence.     
For patients who never experienced a recurrence, chemotherapy was associated with a 60% decreased 
rate of dying.  However, once a recurrence had occurred, having had a history of chemotherapy was not 
associated with all-cause mortality outcome. 
 
The rate of dying was dependent on age at diagnosis but the extent of this effect varied by tumour stage at 
diagnosis (Table 3).   Amongst patients diagnosed with early stage tumours (A & B), there was no 
difference in survival outcomes for those diagnosed younger than 60 years and those diagnosed 60-69 
years.  There was evidence that younger patients had poorer survival outcomes from later stage cancers 
(C & D) compared to those diagnosed 60-69 years.  Patients diagnosed over 70 years of age had poorer 
survival compared to 60-69 years olds for all four cancer stages. 
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The type of surgery performed, year of diagnosis and ASA were also significantly associated with all-
cause mortality after adjusting for cancer stage, age at diagnosis, CMT and recurrence (Table 3).  Patients 
who underwent a low anterior resection died four times faster than patients who had ultralow anterior 
resections and those who had less common procedures, coded as “other” (including proctocolectomy and 
ileal J pouch), died three times faster. Local excision of the cancer was not associated with an increased 
mortality. Improved survival outcomes were observed over time in this cohort although this effect is a 
likely confounded by correlation with hospital, patient and surgeon characteristics (i.e. learning curve) 
that changed in a non-random way over the study period. For each increase of one in ASA score, the 
relative rate of dying increased by 42% in this study cohort after adjusting for the other included 
covariates. 
 
The relative hazard of developing a recurrence, either local or distant, was estimated by a proportional 
hazards regression model (Table 4). Only the resection status (R1) and the use of  chemotherapy were 
associated with a significant increase in recurrence. Therefore, sex, age at diagnosis, curative intent, type 
of operation, height of tumour, extramural venous invasion, radiotherapy, year of diagnosis, ASA, tumour 
stage and positive lymph nodes were not associated with the relative rate of recurrence in this rectal 




The results of this study have indicated that the development of local recurrence in patients with rectal 
cancer is associated with a worse survival than patients developing distant metastases alone. This 
observation was especially strong in patients under the age of 60 years and when the recurrence 
developed within two years of diagnosis. A multivariate analysis of survival demonstrated a number of 
recognized associations (i.e. age, stage, and ASA score). The study also found that recurrence is most 
closely predicted by the resection status and the use of chemotherapy. Of interest was the poor survival 
associated with performing a low versus ultra low anterior resection, a finding not previously noted in the 
literature. This study failed to demonstrate any survival advantage for patients receiving radiotherapy.  
 
It could be argued that cancer survival is mainly dependent on the development of distant metastatic 
disease. Yet this study highlights the strong association between local recurrence and survival. Of those 
patients developing local recurrence, nearly two thirds also had systemic disease at the same time. This is 
a similar rate to that noted in the Dutch TME trial
5
. Untreated local recurrence of a rectal cancer is a fatal 
condition
10
. Table I details a series of clinical trials published over the last 15 years that have evaluated 
various treatment modalities such as surgical technique, chemotherapy and radiotherapy in the 
management of rectal cancer. Many of these trials have extended follow-up periods and their results are 
mature. Of interest is the fact that a majority have shown long-term improvements in local recurrence yet 
this has not translated into a benefit in overall survival
1-6
. Some trials such as the NSABP R03 have 
shown improved disease-free survival but not overall survival
4
. You can debate which is the more 
relevant survival analysis, however, overall survival is such a robust and unbiased outcome measure that 




There are a number of possible explanations for the apparent lack of association between local recurrence 
and survival.  Firstly, that the adjuvant treatments may have a negative effect on long term overall 
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survival and that this is reducing the benefits derived from decreasing the rate of local recurrence. Early 
trials of radiotherapy did show increased rates of morbidity from treatment
12
, however, modern 
techniques are felt to have resolved these problems. An alternative explanation is that the local recurrence 
is not really prevented but rather suppressed, so that it exists in smaller volume and hence not as readily 
diagnosed. Perhaps the rates of recurrence are not reduced at all, only suppressing the disease to a 
subclinical volume. Recurrence can be difficult to diagnose, and small volume disease may contribute to 
systemic disease and a reduced survival.  
 
A number of trials have evaluated predictors of local recurrence following treatment of rectal cancer. 
Perhaps the strongest associations have been found in relation to the tumour stage, the location of the 
tumour to the anal verge, and the resection margin
13-15
. The strongest predictors in this trial were the use 
of chemotherapy and the resection margin. The lack of association of survival on the location of the rectal 
cancer is in discord with a majority of other studies
13-15
. These studies have included multiple surgeons 
whereas this trial was drawn form a single surgeon experience. The advantage of this is that the 
complexity of rectal surgery is more standardized, however, these results are less transferable. The 
association of recurrence with chemotherapy probably relates to the use of such treatment on those 
patients with more advanced disease. Yet, in the era of CMT, it is difficult to accurately define rectal 
cancer staging, as approximately 23% of patients are complete responders to their treatment. The 
association of recurrence with resection margins is well recognized and again noted in this study. 





There are a number of limitations with a study of this nature. Because this is a single surgeon series, its 
findings lack generalizability, and the relative small study size means that it may be underpowered to 
detect some important differences. For example, the extramural vascular invasion (EMV) data has only 
been accurately collected over the last 6 years. Yet in the multivariate analysis it always looked like it 
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was going to stay in the models, but it kept dropping out due to lack of sample size. With only 25 people 
developing local recurrence it meant that the analysis lacked power. Nonetheless, the advantage of this 
dataset is that it was prospectively collected and the patients were intensively followed up. Because of the 
geographical isolation of the study group, few patients were lost to follow-up (3 only). It would be of 
interest to validate these findings on a larger dataset. 
 
In conclusion, over the last two decades the rates of local recurrence have significantly reduced in 
patients with rectal cancer. This has occurred through of a variety of different approaches including 
improved surgery, and the use of adjuvant chemotherapy and radiotherapy. What is difficult to know is 
which of these factors is playing the most dominant role in these reductions. This study has shown that 
local recurrence is one of the most important predictors for survival in patients with rectal cancer, yet this 
is in contrast to recent trials indicating improved local recurrence rates without improvements in survival. 
The results of this trial need to be validated, and if they are, then we should continue to focus attention on 
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Table I. A Selection of Clinical Trials on Patients with Rectal Cancer that Evaluated Radiotherapy and/or 
Chemotherapy. 
 










Pre RadioRx 866 5 58% vs 48% 
p=0.004 
11% vs 27% 
p<0.001 
 NSABP R-022 Post CMT vs 
RadioRx 
694 8 53% vs 51% 
ns 







Pre vs Post CMT 823 11 60% vs 60% 
ns 
7% vs 10% 
p=0.048 
 NSABP R-034  Pre vs Post CMT 267 8 74% vs 66% 
ns 
11% vs 11% 
ns 




Pre RadioRx vs 
TME 
1861 12 48% vs 49% 
ns 
5% vs 11% 
p=0.0001 




Pre CMT vs Post 
ChemoRx 
1753 6 66% vs 66% 
ns 
11% vs 15% 
p=0.0001 
 






Table 2.  Summary characteristics of the study cohort (N=483) and log rank test p values of equality of 
survival function. 
 Cases  Died   Cases  Died  




Variable N %  N p - 
value 
Sex     Surgery status      
Male 281 58.2  110  0.163 Emergency 18 3.7  11 0.015 
Female 202 41.8  69  Elective 465 96.3  168  
           
Age group     Resection status      
<55 103 21.3  22 0.010 R0 439 90.9  147 <0.001 
55 - 64 112 23.2  24  R1 44 9.1  32  
65 - 74 155 32.1  58        
75+ 113 23.4  75  Height of 
tumour 
     
     2 - 5 cm 106 21.9  40 0.399 
Year diagnosed     6 – 10 cm 208 43.1  65  
1996 - 2001 185 38.3  102 0.006 11 – 18 cm 123 25.5  47  
2002 - 2006 184 38.1  72  Not recorded 46 9.5  27  
2007 - 2012 114 23.6  5        
     Lymph nodes      
Stage     No/unknown 434 89.9  167 0.422 
A 168 34.8  44 <0.001 Yes 49 10.1  12  
B 119 24.6  45        
C 126 26.1  34  Extramural 
veins 
     
D 70 14.5  56  No 116 24.0  6 0.004 
     Yes 11 2.3  3  
ASA     Not recorded 356 73.7  170  
1 90 18.6  12 <0.001       
2 242 50.1  79  Curative intent      
3 131 27.1  74  No 70 14.5  56 <0.001 
4 20 4.1  14  Yes 413 85.5  123  
           
Operation type     Radiotherapy      
Ultralow AR 267 55.3  73 <0.001 No  293 60.7  117 0.175 
Low AR 21 4.3  12  Yes 190 39.3  62  
High AR 33 6.8  14        
Abdominoperineal 62 12.8  27  Chemotherapy      
Hartmann's 20 4.1  16  No  260 53.8  111 0.593 
Other 20 4.1  8  Yes 223 46.2  68  
Primary local excision 60 12.4  29        
     Recurrence type      
Hospital     None 412 85.3  133 <0.001 
Private (06-12) 127 26.3  7 0.001 Local  25 5.2  17  




Table 3.  Relative hazard of dying following a diagnosis of rectal cancer by factors present at time of 
surgery and recurrence status (as a time-varying state) as estimated by a proportional hazards regression 
model and using age as the time scale. 
Variable Within variable
a
 HR 95%CI p-value 
Recurrence state Age at diagnosis    
Local vs none <60 years 54.2  11.6 - 253.1 0.000  
 60-69 years  0.8  0.1 - 6.8 0.800  
 70+ years 28.3  9.8 - 82.1 0.000  
Distant vs none  <60 years 18.6  4.3 - 80.1 0.000  
 60-69 years  4.0  1.4 - 10.9 0.007  
 70+ years  8.0  2.3 - 28.0 0.001  
     
Chemotherapy Recurrence state    
Yes vs No None 0.5 0.3 - 0.9 0.013 
 Local 1.0 0.2 - 4.9 0.994 
 Distant 0.5 0.1 - 2.9 0.479 
     
Age at diagnosis Stage    
<60 years vs 60-69 years A  2.9  0.3 - 27.8 0.359 
 B  6.5  1.0 - 42.0 0.048 
 C 11.6  2.3 - 59.6 0.003 
 D  7.1  1.1 - 44.8 0.038 
70+ years vs 60-69 years A 11.4  2.7 - 49.4 0.001 
 B  8.9  2.5 - 32.0 0.001 
 C 15.2  4.3 - 53.4 0.000 
 D  3.9  1.3 - 11.6 0.015 
     
Operation type     
Ultralow AR  1.0 referent  
Low AR  4.1 2.2 - 7.5 0.000 
High AR  1.1 0.5 - 2.4 0.778 
Abdominoperineal  0.9 0.5 - 1.6 0.642 
Hartmann's  1.5 0.7 - 3.3 0.268 
Other  2.9 1.6 - 5.4 0.001 
Primary local excision  1.2 0.7 - 2.2 0.458 
     
Year of diagnosis  0.9 0.9-1.0 0.002 
ASA  1.4 1.1-1.9 0.018 
a 
The relative rate all-cause mortality for some variables was modified by others, that is, a significant 
interaction was present.  Interaction terms were present between age at diagnosis and recurrence state, 
recurrence state and preop chemotherapy and age diagnosis and tumour stage.  Hazard ratios are 
presented within strata of the modifying variables. 
Only variables significant at the 5% level were included in the final models. 
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Table 4.  Relative hazard of developing a recurrence of tumour, either local or distant by factors present at 
time of surgery as estimated by a proportional hazards regression model and using time since diagnosis 
the time scale. 
 
Variable HR 95%CI p-value 
Chemotherapy    
No 1.0 ref  
Yes 3.8 2.2-6.7 <0.001 
    
Resection margin    
R0 1.0 ref  
R1 3.1 1.7-5.6 <0.001 
    
 
 
Only variables significant at the 5% level were included in the final models, thus sex, age at diagnosis, 
curative intent, type of operation, height of tumour, extramural venous invasion, radiotherapy, year of 
diagnosis, ASA, tumour stage and positive lymph nodes were not associated with the relative rate of 




Figure 1. The survival experience of the rectal cancer cohort by whether patients have remained 
recurrence free (solid line), after recording a distant recurrence (dashed line) and after recording a local 
recurrence (dotted line) represented graphically from time since diagnosis using A) Kaplan-Meier 
estimates of the survival proportions and B) a smoothed hazard function (rate of dying). 95% confidence 






















Figure 2. The estimated age-specific mortality rate (hazard rate) for the rectal cancer cohort using age as 
the time scale by whether patients have remained recurrence free (solid line), after recording a distant 
recurrence (dashed line) and after recording a local recurrence (dotted line). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 



